Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.